1972PubMedRequires access

Isoniazid chemoprophylaxis of tuberculosis.

Daniel E. Jenkins, Frank F. Davidson

Open publisher page 10 citations

Abstract

A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection. Chemical trials have demonstrated the effectiveness of chemoprophylaxis in groups where there is a relatively high risk of active tuberculosis. However, only the practicing physician can identify and offer chemoprophylaxis to many other susceptible persons. Even if the patient is a candidate for isoniazid, the risk of developing tuberculosis must be weighed against the cost and possible adverse effects of the drug. If isoniazid is given, the physician must be alert to the signs of possible drug toxicity. If isoniazid is not given, he must anticipate the development of active tuberculosis in susceptible persons.

About this research paper

What this paper is about

A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection. Chemical trials have demonstrated the effectiveness of chemoprophylaxis in groups where there is a relatively high risk of active tuberculosis. However, only the practicing physician can identify and offer chemoprophylaxis to many other susceptible persons. Even if the patient is a candidate for isoniazid, the risk of developing tuberculosis must be weighed against the cost and possible adverse effects of the drug. If isoniazid is given, the physician must be alert to the signs of possible drug toxicity. If isoniazid is not given, he must anticipate the development of active tuberculosis in susceptible persons.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection. Chemical trials have demonstrated the effectiveness of chemoprophylaxis in groups where there is a relatively high risk of active tuberculosis. However, only the practicing physician can identify and offer chemoprophylaxis to many other susceptible persons. Even if the patient is a candidate for isoniazid, the risk of developing tuberculosis must be weighed against the cost and possible adverse effects of the drug. If isoniazid is given, the physician must be alert to the signs of possible drug toxicity. If isoniazid is not given, he must anticipate the development of active tuberculosis in susceptible persons.

Key concepts: Chemoprophylaxis, Isoniazid, Tuberculosis, Medicine, Tuberculin, Tuberculosis prevention, Intensive care medicine, Surgery

Related papers

Back to paper searchBrowse research topicsOriginal source
Isoniazid chemoprophylaxis of tuberculosis. — Research Paper | ScholarLens